NCT07500805

UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

An Exploratory Clinical Study to Evaluate the Safety and Preliminary Efficacy of UCL70805F in the Treatment of Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (estimated)
• Sponsor: UTC Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of UCL70805F in patients with CD70-positive advanced renal clear cell carcinoma.

Detailed description

This study will include two parts, dose escalation phase (modified "3+3" design) followed by a dose expansion phase. All eligible participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, followed by a single intravenous infusion of UCL70805F. The recommended phase 2 dose (RP2D) will be determined during the dose escalation phase. In the dose expansion phase, one or two dose levels may be selected to further characterize the safety profile and evaluate the efficacy of UCL70805F.

Conditions

• CD70-positive Advanced Renal Clear Cell Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	UCL70805F	D0: 5×10\^4 cells ～ 4×10\^5 cells

Timeline

• Start date: 2026-05-01
• Primary completion: 2028-05-01
• Completion: 2029-05-01
• First posted: 2026-03-30
• Last updated: 2026-03-30

Locations

1 site across 1 country: China